Can β-nicotinamide mononucleotide (NMN) supplementation increase NAD concentrations and improve health in middle-aged healthy adults, and what are its safety and efficacy at different doses?
Nicotinamide Mononucleotide, a randomized, double-blind, placebo-controlled trial in 80 healthy middle-aged adults (GeroScience 2022, PMID 36482258) — walking distance significantly increased in all NMN groups compared to placebo, with the longest distances in the 600 mg and 900 mg groups. HOMA-IR showed no significant differences, while SF-36 scores indicated significantly better health in all NMN groups compared to placebo.
Source: GeroScience 2022, PMID 36482258 ↗ · Research map · How Magellan grades evidence · evidence confidence: high
GeroScience · 2022 · PMID 36482258 · DOI 10.1007/s11357-022-00705-1
Daily NMN supplementation up to 900 mg is safe and increases NAD levels, physical performance, and subjective health in middle-aged adults, with 600 mg showing the highest efficacy.
The question
Can β-nicotinamide mononucleotide (NMN) supplementation increase NAD concentrations and improve health in middle-aged healthy adults, and what are its safety and efficacy at different doses?
What they tested
NMN supplementation will increase NAD concentrations and improve healthspan parameters in humans, similar to findings in animal studies, and will be safe and well-tolerated.
How they did it
This was a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. 80 healthy middle-aged adults were randomized to receive daily oral doses of placebo, 300 mg, 600 mg, or 900 mg NMN for 60 days. Blood NAD concentration was the primary outcome, while secondary outcomes included safety, tolerability, physical performance (six-minute walking test), blood biological age, HOMA-IR, and subjective general health (SF-36).
What they found
Blood NAD concentrations significantly increased in all NMN-treated groups at days 30 and 60 compared to placebo and baseline, with the highest concentrations in the 600 mg and 900 mg groups. No safety issues were observed, and NMN was well tolerated. Walking distance significantly increased in all NMN groups compared to placebo, with the longest distances in the 600 mg and 900 mg groups. Blood biological age increased in the placebo group but remained unchanged in NMN groups. HOMA-IR showed no significant differences, while SF-36 scores indicated significantly better health in all NMN groups compared to placebo.
| 300 mg NMN | 300 | |
|---|---|---|
| 600 mg NMN | 600 | |
| 900 mg NMN | 900 |
The abstract indicates that blood NAD concentrations and walking distances were highest in the 600 mg and 900 mg NMN groups, and clinical efficacy reached highest at 600 mg daily.
What it means
NMN supplementation increases blood NAD concentrations and is safe and well tolerated at oral doses up to 900 mg daily in healthy middle-aged adults. Clinical efficacy, including improvements in physical performance and subjective health, appears highest at a dose of 600 mg daily.
Limitations
The abstract does not explicitly state any limitations of the study.
Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.
The paper at a glance
| Title | The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. |
|---|---|
| Journal | GeroScience |
| Year | 2022 |
| PMID | 36482258 ↗ |
| DOI | 10.1007/s11357-022-00705-1 ↗ |
| Topic | NAD⁺, sirtuins & cellular energy |
Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗
Where Magellan uses this paper
This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.
Nicotinamide Mononucleotide (NMN)
In randomized controlled trials, NMN reliably increases blood NAD+ levels and has generally been well tolerated at oral doses up to roughly 900-1250 mg/day, with some trials reporting modest improvements in skeletal-muscle insulin sensitivity, walking speed, aerobic capacity, sleep quality, and diastolic blood…
All-in-One Longevity Formulation
Several of NOVOS Core's ingredients have genuine, though mostly early-stage, human or animal evidence relevant to aging: trials of GlyNAC (glycine plus N-acetylcysteine) improved oxidative stress, mitochondrial function, strength and walking performance in older adults — though at glycine doses far above what the…
Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic…
Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic…
Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic…
Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic…
Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic…
Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic…
Research describes the compound or intervention studied. It is not a claim about any specific product.
Molecules & mechanisms in this paper
Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.
Cite this page
These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.
Magellan Longevity. (2026). Can β-nicotinamide mononucleotide (NMN) supplementation increase NAD concentrations and improve health in middle-aged healthy adults, and what are its safety and efficacy at different doses? [Plain-English summary of GeroScience 2022, PMID 36482258, DOI 10.1007/s11357-022-00705-1]. Magellan Longevity. https://magellanlongevity.com/study/nmn_trial.html@misc{magellan_nmn_trial,
title = {Can β-nicotinamide mononucleotide (NMN) supplementation increase NAD concentrations and improve health in middle-aged healthy adults, and what are its safety and efficacy at different doses?},
author = {{Magellan Longevity}},
year = {2026},
howpublished = {\url{https://magellanlongevity.com/study/nmn_trial.html}},
note = {Plain-English summary of PubMed PMID 36482258; DOI 10.1007/s11357-022-00705-1; GeroScience 2022. Reviewed by Gabriel Radu, DO},
urldate = {2026-08-11}
}https://magellanlongevity.com/study/nmn_trial.htmlRelated studies in the Magellan library
- Caloric restriction, resveratrol and melatonin: Role of SIRT1 and implications for aging and…Mechanisms of Ageing and Development · 2015 · PMID 25824609
- NAD metabolism and arterial stiffness after long-term nicotinamide mononucleotide…Sci Rep · 2023 · PMID 36797393
- Towards personalized NMN supplementation: nicotinamide adenine dinucleotide (NAD) concentrationFrontiers in Aging · 2024 · PMID 38430946
- The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an…Advances in Nutrition · 2023 · PMID 37619764
- Rejuvant, a potential life-extending compound formulation with alpha-ketoglutarate and…Aging · 2021 · PMID 34847066
- Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione…The Journals of Gerontology: Series A · 2022 · PMID 35975308
All 17 Magellan summaries on nad⁺, sirtuins & cellular energy →
Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →